Net sales rose year-over-year for Jan–Sep 2025, with improved operating results and positive Q3 cash flow. Portfolio companies made clinical and business advances, while the listed portfolio rebounded in Q3. Equity ratio remains high at 86%.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.